ArriVent BioPharma, Inc. (NASDAQ:AVBP – Get Free Report)’s stock price reached a new 52-week low on Tuesday after Guggenheim lowered their price target on the stock from $30.00 to $28.00. Guggenheim currently has a buy rating on the stock. ArriVent BioPharma traded as low as $10.91 and last traded at $10.96, with a volume of 92,698 shares trading hands. The stock had previously closed at $11.56.
Several other brokerages also recently issued reports on AVBP. HC Wainwright dropped their target price on shares of ArriVent BioPharma from $47.00 to $27.00 and set a “buy” rating on the stock in a research note on Thursday, October 8th. Citigroup reduced their price target on shares of ArriVent BioPharma from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, October 7th. Cantor Fitzgerald restated an “overweight” rating on shares of ArriVent BioPharma in a report on Thursday. BTIG Research reaffirmed a “buy” rating and issued a $29.00 price objective on shares of ArriVent BioPharma in a research report on Friday, October 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Thursday, October 15th. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, ArriVent BioPharma has an average rating of “Moderate Buy” and an average target price of $24.67.
Read Our Latest Stock Report on AVBP
Institutional Inflows and Outflows
ArriVent BioPharma Trading Down 3.4%
The stock has a 50 day simple moving average of $20.97 and a 200-day simple moving average of $26.35. The firm has a market capitalization of $577.71 million, a P/E ratio of -3.10 and a beta of 1.66.
ArriVent BioPharma (NASDAQ:AVBP – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24. The business had revenue of $5.00 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, sell-side analysts expect that ArriVent BioPharma, Inc. will post -3.81 earnings per share for the current fiscal year.
ArriVent BioPharma Company Profile
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.
See Also
- Five stocks we like better than ArriVent BioPharma
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for ArriVent BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArriVent BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
